| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8458801 | Radiotherapy and Oncology | 2018 | 6 Pages |
Abstract
Dose-escalated prostate SABR was associated with lower nPSAs but no difference in BF, OS, CSS or MFS. PSA <0.4 at 4â¯years was a predictor of biochemical control. Half of patients with BF were successfully salvaged. Given that this is a favorable-risk cohort, longer follow-up will be needed to see if the lower nPSA translates into lower BF rates.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Yasir Alayed, Patrick Cheung, Geordi Pang, Alexandre Mamedov, Laura D'Alimonte, Andrea Deabreu, Kristina Commisso, Angela Commisso, Liang Zhang, Harvey C. Quon, Hima Bindu Musunuru, Joelle Helou, D. Andrew Loblaw,